Our PDO Monolayer is an advanced and rapid solution that enables the proliferation and maturation of stem cells from intestinal crypts sourced from patient biopsies into a fully differentiated human epithelium. This process closely mimics the natural composition of in vivo gut epithelium, encompassing various types of intestinal cells. What sets our PDO Monolayer apart is its unique ability to be generated from a diverse biobank of IBD patients, making it the sole in vitro model that accurately represents the characteristics of the patient population.
Utilize our PDO Monolayer to model inflammation response, toxicity, and barrier function, providing you with the confidence you need to advance your lead candidates effectively.
The development of successful therapies requires evaluating a drug’s impact on multiple cell or tissue types. Modeling these intricate interactions often compromises scalability, posing a challenge for preclinical drug development. We offer unique organoid co-cultures to facilitate the development of candidates targeting inflammatory fibroblasts and immune cells within the gut epithelial microenvironment. Additionally, we can model host-microbiome interactions to screen for preventive therapies in IBD.